Lung Biopsy Systems Market
By Product Type;
Core Needle Biopsy Devices, Fine Needle Aspiration Biopsy Devices, Surgical Biopsy Devices and Vacuum-Assisted Biopsy DevicesBy Procedure Type;
Needle Biopsy, Open Biopsy, Thoracoscopic Biopsy and Transbronchial BiopsyBy Technology;
Ultrasound and StereotacticBy End Use;
Cancer Research Centers, Hospitals, Specialty Clinics and OthersBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2021 - 2031).Lung Biopsy Systems Market Overview
Lung Biopsy Systems Market (USD Million)
Lung Biopsy Systems Market was valued at USD 3,472.13 million in the year 2024. The size of this market is expected to increase to USD 7,772.23 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 12.2%.
Lung Biopsy Systems Market
*Market size in USD million
CAGR 12.2 %
Study Period | 2025 - 2031 |
---|---|
Base Year | 2024 |
CAGR (%) | 12.2 % |
Market Size (2024) | USD 3,472.13 Million |
Market Size (2031) | USD 7,772.23 Million |
Market Concentration | Low |
Report Pages | 311 |
Major Players
- Medtronic
- DTR Medical
- B. Braun Melsungen AG
- Argon Medical Devices
- Cardinal Health
- Hologic, Inc.
- Fujifilm Medical Systems
- Olympus Corporation
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Lung Biopsy Systems Market
Fragmented - Highly competitive market without dominant players
The Lung Biopsy Systems Market is witnessing accelerated adoption as healthcare providers emphasize early detection of lung conditions, which now represent over 60% of diagnostic evaluations. The ability to perform precise and minimally invasive procedures makes these systems vital in medical diagnostics. Their increasing use reflects a wider trend toward improved clinical outcomes through advanced tools. As innovation becomes central to healthcare delivery, the demand for lung biopsy systems continues to rise rapidly.
Tech-Driven Advancements Powering Market Innovation
Modern systems with robotic precision and real-time imaging guidance are now present in more than 55% of advanced medical centers. These technologies provide a significant boost in diagnostic reliability and reduce repeat procedure rates. The continued development of such tools creates space for strategic innovation and partnership-driven product enhancement. The focus remains on boosting procedural efficiency through technological advancements, strengthening the market's foundation for the coming years.
Collaborative Strategies Driving Industry Transformation
More than 50% of recent development initiatives are supported by collaborations and partnerships, enabling rapid advancements in biopsy accuracy. Through joint development agreements and mergers, companies are introducing next-gen systems with improved tissue sampling capabilities. These alliances are enabling market leaders to scale faster and introduce cutting-edge technologies, reinforcing a strong ecosystem centered on collaborative innovation and expansion.
Innovation and Growth Forecast Strong for Future Outlook
With over 58% of healthcare centers planning to upgrade their diagnostic capabilities, the market outlook for lung biopsy systems is promising. There is strong momentum toward non-invasive innovations focused on improving efficiency and patient safety. Ongoing research and development in needle design and targeting mechanisms is expected to drive the next wave of technological breakthroughs. This progress supports the long-term growth, expansion, and strategic evolution of the lung biopsy systems space.
Lung Biopsy Systems Market Recent Developments
-
In May 2024, The VERITAS study reveals that Medtronic's fluoroscopic navigation platform provides a safer lung biopsy experience with equivalent diagnostic yield compared to CT-guided biopsies. The trial demonstrates non-inferiority and fewer complications for electromagnetic navigation bronchoscopy in diagnosing lung nodules.
-
In October 2024, Cook County Health celebrated the launch of the Intuitive Surgical ION Navigational Bronchoscopy platform, enhancing lung cancer biopsy procedures. This advanced technology improved diagnosis accuracy and safety, promoting early detection and better outcomes for patients at Stroger Hospital.
Lung Biopsy Systems Market Segment Analysis
In this report, the Lung Biopsy Systems Market has been segmented by Product Type, Procedure Type, End Use, and Geography.
Lung Biopsy Systems Market, Segmentation by Product Type
The Lung Biopsy Systems Market has been segmented by Product Type into Core Needle Biopsy Devices, Fine Needle Aspiration Biopsy Devices, Surgical Biopsy Devices, and Vacuum-Assisted Biopsy Devices
Core Needle Biopsy Devices
Core needle biopsy devices are widely used for acquiring tissue samples in cases of suspected lung cancer or abnormalities. These devices offer higher diagnostic accuracy compared to other methods due to their ability to retrieve larger tissue samples. They are commonly preferred in outpatient settings, ensuring minimal discomfort and faster recovery. The market for these devices is growing with the increasing need for early-stage cancer detection.
Fine Needle Aspiration Biopsy Devices
Fine needle aspiration biopsy devices are favored for their minimally invasive nature and cost-efficiency. These devices are often used in cases where non-solid lung nodules or cystic lesions need evaluation. They are highly recommended for patients who are not ideal candidates for surgical procedures. The growing geriatric population and demand for low-risk diagnostic procedures are propelling this segment.
Surgical Biopsy Devices
Surgical biopsy devices are typically utilized when non-surgical biopsy results are inconclusive or inadequate. This category is crucial in obtaining comprehensive tissue samples during thoracotomy or VATS (Video-Assisted Thoracic Surgery). While more invasive, the precision offered supports advanced diagnosis and staging. The market is driven by increasing adoption of robot-assisted surgical platforms.
Vacuum-Assisted Biopsy Devices
Vacuum-assisted biopsy devices enable the removal of multiple tissue samples in a single insertion, enhancing patient comfort and diagnostic yield. They are gaining traction for their efficiency and reduced procedural time. These systems are particularly beneficial in deep lung lesion biopsies where access is challenging. The integration of imaging guidance with these devices improves their clinical utility.
Lung Biopsy Systems Market, Segmentation by Procedure Type
The Lung Biopsy Systems Market has been segmented by Procedure Type into Needle Biopsy, Open Biopsy, Thoracoscopic Biopsy, and Transbronchial Biopsy
Needle Biopsy
Needle biopsy procedures dominate the market due to their minimally invasive approach and high diagnostic effectiveness. These techniques include both fine and core needle biopsies guided by imaging modalities like CT or ultrasound. Their growing use in outpatient and day-care settings drives adoption. The market is seeing advancements in needle design for precise tissue targeting.
Open Biopsy
Open biopsy is a traditional method often employed when less invasive procedures fail or yield non-diagnostic results. It provides ample tissue for histopathological evaluation, making it invaluable for complex cases. However, it involves hospital stay and longer recovery time. Despite being invasive, it remains essential in confirmatory diagnostics.
Thoracoscopic Biopsy
Thoracoscopic or VATS biopsy procedures are witnessing growth due to enhanced visualization and lower postoperative complications. These minimally invasive surgeries allow for accurate biopsy of peripheral lung lesions. Thoracoscopic methods are increasingly used in cancer staging and diagnosis, supported by the adoption of advanced thoracoscopy tools.
Transbronchial Biopsy
Transbronchial biopsy involves passing a bronchoscope through airways to access internal lung tissues. It is instrumental in diagnosing interstitial lung disease and certain infections. The procedure’s safety profile and real-time imaging support have expanded its clinical applications. Rising use in pulmonology clinics is boosting this segment.
Lung Biopsy Systems Market, Segmentation by End Use
The Lung Biopsy Systems Market has been segmented by End Use into Cancer Research Centers, Hospitals, Specialty Clinics, and Others
Cancer Research Centers
Cancer research centers utilize lung biopsy systems for both clinical and investigational purposes. These facilities demand devices that offer precise and repeatable results for biomarker testing and genetic profiling. Increasing investments in oncology research and personalized medicine are driving this segment forward.
Hospitals
Hospitals represent the largest user base due to their capacity to handle both invasive and non-invasive biopsy procedures. The availability of advanced imaging systems and surgical infrastructure supports their dominant position. Integration with electronic health records and multidisciplinary diagnostics are further expanding their role.
Specialty Clinics
Specialty clinics, particularly those focused on pulmonology and oncology, are emerging as key adopters of portable biopsy systems. These clinics prefer solutions that allow rapid diagnostic turnaround with minimal infrastructure. As more procedures shift to outpatient care models, demand from this segment is poised to grow.
Others
This category includes diagnostic labs, academic institutions, and contract research organizations. Their demand stems from the need for flexible and research-grade biopsy solutions. They often require systems compatible with high-throughput analysis, especially in clinical trials and pre-clinical studies.
Lung Biopsy Systems Market, Segmentation by Geography
In this report, the Lung Biopsy Systems Market has been segmented by Geography into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America
Regions and Countries Analyzed in this Report
Lung Biopsy Systems Market Share (%), by Geographical Region
North America
North America accounts for the largest share of the lung biopsy systems market at 38.4%, driven by strong healthcare infrastructure and high diagnostic awareness. Widespread adoption of advanced biopsy techniques and favorable reimbursement policies further boost growth. The region also benefits from early adoption of robotic-assisted biopsy systems.
Europe
Europe represents approximately 27.6% of the global market and benefits from well-established oncology centers and favorable clinical guidelines. Increasing incidence of lung cancer and government support for early screening programs contribute to market expansion. Technological partnerships and clinical research projects are also spurring demand.
Asia Pacific
Asia Pacific holds a share of 21.3% and is expected to grow at the fastest CAGR due to rising healthcare expenditures and growing awareness of minimally invasive diagnostics. Urbanization, coupled with increasing prevalence of pulmonary diseases, is boosting device penetration across the region.
Middle East & Africa
Middle East & Africa account for around 6.7% of the market. Though relatively nascent, the segment is experiencing growth due to investments in healthcare infrastructure and the emergence of specialized clinics. Efforts to increase cancer diagnosis rates in developing nations are also contributing.
Latin America
Latin America contributes about 6% to the market and shows promising growth due to increasing cases of lung cancer and adoption of biopsy technologies in public hospitals. Brazil and Mexico lead in market share, driven by healthcare modernization and growing diagnostic imaging access.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Lung Biopsy Systems Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers
- More lung diseases, like cancer, mean more early treatment
- Better biopsy technology means less invasive procedures
- Aging population leads to more respiratory issues
-
More awareness about early disease detection - With advancements in healthcare education and increasing public health campaigns, there's a noticeable surge in awareness regarding the importance of early disease detection, particularly concerning lung diseases like cancer.
Efforts from healthcare organizations, government initiatives, and non-profit organizations have significantly contributed to educating individuals about the signs and symptoms of lung diseases, emphasizing the benefits of early screening and diagnosis. This heightened awareness encourages individuals to seek medical attention at the earliest signs of respiratory issues, leading to timely interventions, improved treatment outcomes, and potentially saving lives.
Restraints
- Shortage of skilled professionals
- Concerns about safety, especially in older patients
-
Limited resources in rural areas -Despite the progress in healthcare infrastructure, rural areas often face significant challenges due to limited resources, including healthcare facilities, trained medical professionals, and diagnostic equipment. This scarcity poses a barrier to accessing timely and quality healthcare services, including lung disease diagnosis and treatment.
Residents of rural areas may have to travel long distances to reach healthcare facilities capable of performing lung biopsies, leading to delays in diagnosis and treatment initiation. Addressing this issue requires concerted efforts from governments, healthcare organizations, and non-profit entities to improve healthcare accessibility in rural regions through initiatives such as mobile healthcare units, telemedicine services, and training programs for local healthcare providers.
Opportunities
- New biopsy techniques create opportunities
- Partnerships between providers and tech firms expand reach
- AI improves diagnosis
-
Personalized medicine offers new lung cancer treatments - Advancements in medical research and technology have paved the way for personalized medicine approaches in the treatment of lung cancer. These innovative therapies aim to tailor treatment regimens based on individual genetic makeup, tumor characteristics, and other factors, allowing for more precise and effective interventions.
Personalized medicine techniques, such as targeted therapy and immunotherapy, have revolutionized the landscape of lung cancer treatment, offering patients improved survival rates and reduced side effects compared to traditional chemotherapy. With ongoing research and development in this field, personalized medicine continues to unlock new treatment options and therapeutic strategies, heralding a promising era in the fight against lung cancer.
Competitive Landscape Analysis
Key players in Global Lung Biopsy Systems Market include
- Medtronic
- DTR Medical
- B. Braun Melsungen AG
- Argon Medical Devices
- Cardinal Health
- Hologic, Inc.
- Fujifilm Medical Systems
- Olympus Corporation
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Procedure Type
- Market Snapshot, By End Use
- Market Snapshot, By Region
- Lung Biopsy Systems Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- More lung diseases, like cancer, mean more early treatment
- Better biopsy technology means less invasive procedures
- Aging population leads to more respiratory issues
- More awareness about early disease detection
- Restraints
- Shortage of skilled professionals
- Concerns about safety, especially in older patients
- Limited resources in rural areas
- Opportunities
- New biopsy techniques create opportunities
- Partnerships between providers and tech firms expand reach
- AI improves diagnosis
- Personalized medicine offers new lung cancer treatments
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Lung Biopsy Systems Market, By Product Type, 2021 - 2031 (USD Million)
- Core Needle Biopsy Devices
- Fine Needle Aspiration Biopsy Devices
- Surgical Biopsy Devices
- Vacuum-Assisted Biopsy Devices
- Lung Biopsy Systems Market, By Procedure Type, 2021 - 2031 (USD Million)
- Needle Biopsy
- Open Biopsy
- Thoracoscopic Biopsy
- Transbronchial Biopsy
-
Lung Biopsy Systems Market, By Technology, 2021 - 2031 (USD Million)
-
Ultrasound
-
Stereotactic
-
- Lung Biopsy Systems Market, By End Use, 2021 - 2031 (USD Million)
- Cancer Research Centers
- Hospitals
- Specialty Clinics
- Others
- Lung Biopsy Systems Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Lung Biopsy Systems Market, By Product Type, 2021 - 2031 (USD Million)
- Competitive Landscape Analysis
- Company Profiles
- Medtronic
- DTR Medical
- B. Braun Melsungen AG
- Argon Medical Devices
- Cardinal Health
- Hologic, Inc.
- Fujifilm Medical Systems
- Olympus Corporation
- Company Profiles
- Analyst Views
- Future Outlook of the Market